New Clinical Oncology Findings from Basit Chaudhry and Co-Authors Described (Biosimilar adoption and provider performance in Medicare value-based payment models): Clinical Oncology

2026 JUN 04 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Data detailed on Clinical Oncology have been presented. According to news reporting from Bethesda, Maryland, by NewsRx journalists, research stated, “To quantify the impact of biosimilar adoption on oncology provider financial risk under the Oncology Care Model (OCM) using real-world data. Retrospective study of Medicare fee-for-service beneficiaries potentially eligible for an OCM episode of care initiating between January 2019 and June 2021.”

The news correspondents obtained a quote from the research, “Cancer treatment episodes were identified from the Medicare 5% Limited Data Set (LDS). The study sample consisted of episodes with use of any of the following agents or their biosimilars: bevacizumab, rituximab, trastuzumab, epoetin alfa, filgrastim, and pegfilgrastim. Financial risk was defined as the difference in observed total cost of care vs OCM benchmark episode cost. The primary outcome was the difference in financial risk (expressed in nominal US$) under observed use of reference agents and/or biosimilars vs hypothetical use of 100% reference product. The sample included 8851 episodes. Biosimilar adoption resulted in a mean cost reduction of $1023 per 6-month episode vs hypothetical 100% use of reference agents. Biosimilar use increased markedly over the study horizon-with use in 65% of episodes initiating in half 1 (H1) of 2021. The mean cost of care reduction in episodes initiating in H1 2021 ($2060; 4.1% of mean episode benchmark price) improved nearly 10-fold vs H1 2019 ($201; 0.4% of mean episode benchmark price).”

According to the news reporters, the research concluded: “Rapid adoption of biosimilars for Medicare beneficiaries included in the LDS led to substantial cost savings for cancer episodes evaluated under the OCM methods-suggesting that adoption of biosimilars is a key strategy that providers should consider to manage financial risk in value-based payment models.”

This research has been peer-reviewed.

For more information on this research see: Biosimilar adoption and provider performance in Medicare value-based payment models. The American Journal of Managed Care, 2026;32(5):292-297. The American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

Our news journalists report that additional information may be obtained by contacting Basit Chaudhry, Tuple Health, 4800 Hampden Ln, Ste 200, Bethesda, MD 20814. Additional authors for this research include Andrew Yue, Ahmed Shelbaya, Lisa Tran and Joshua A. Roth.

Publisher contact information for the The American Journal of Managed Care is: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)